The ADAMTS8 antibody is a tool used to detect ADAMTS8 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 8), a secreted protease involved in extracellular matrix (ECM) remodeling and cellular signaling. ADAMTS8 belongs to the ADAMTS family, characterized by a conserved structure including a propeptide, metalloproteinase, disintegrin-like, and thrombospondin type-1 repeat (TSR) domains. It plays roles in angiogenesis inhibition, tumor suppression, and tissue repair by cleaving ECM components like aggrecan and versican. Dysregulation of ADAMTS8 is linked to cancer progression, cardiovascular diseases, and fibrosis, making it a target for therapeutic and diagnostic research.
ADAMTS8 antibodies are typically generated against specific epitopes, such as peptide sequences within its catalytic or TSR domains, using recombinant proteins or synthetic peptides as immunogens. These antibodies are validated for applications like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and ELISA to study protein expression, localization, and function in tissues or cell lines. Researchers use them to explore ADAMTS8's role in disease models, such as assessing its downregulation in tumors or its anti-angiogenic effects in endothelial cell assays. Specificity is confirmed via knockout controls or siRNA knockdown. As a reagent, ADAMTS8 antibodies aid in understanding its ECM regulatory mechanisms and potential as a biomarker or therapeutic target.